|
|
Post by letitride on Aug 2, 2022 19:05:58 GMT -5
It would be nice if Mike and Steve would post a selfie of them smiling with a big high Five to give a confirmation of one of the greatest quarters.
|
|
|
|
Post by georgethenight2 on Aug 2, 2022 20:46:57 GMT -5
i just MC to give some guidance for once during his tenure. The rest and grow strategy seems to be working, but WS wants something these stick there teeth in. Time to feed the wolves Mike.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Aug 3, 2022 11:58:45 GMT -5
i just MC to give some guidance for once during his tenure. The rest and grow strategy seems to be working, but WS wants something these stick there teeth in. Time to feed the wolves Mike. I remember once when he gave guidance. He muffed it pretty bad. I totally agree with you, George. I would love to see it, too. Isn't giving guidance like a key task for CEO's? Maybe he slept through that class at Wharton. |
|
|
|
Post by Actual Investor on Aug 3, 2022 12:25:19 GMT -5
I read as information about his business unit rather than corporate. He recognized the rep who led the charge which indicates a smaller unit than the entire company. Just an observation from an old time sales manager/CEO.
|
|
|
|
Post by akemp3000 on Aug 3, 2022 13:41:56 GMT -5
A quick search for ceo guidance for investors shows this, "Companies should tell investors when guidance will be given so investors know what to expect. For example, a company should tell investors that its policy is to give guidance once a year in March concurrently with the year-end earnings release, covering expectations for the year in process." IMO, there's likely a difference in providing guidance whether the company is large and well established or small and emerging.
|
|
|
|
Post by robbmo on Aug 4, 2022 9:43:31 GMT -5
I read as information about his business unit rather than corporate. He recognized the rep who led the charge which indicates a smaller unit than the entire company. Just an observation from an old time sales manager/CEO. Fyi, Matt Bazzani is his boss. |
|
|
|
Post by mango on Aug 4, 2022 11:16:51 GMT -5
i just MC to give some guidance for once during his tenure. The rest and grow strategy seems to be working, but WS wants something these stick there teeth in. Time to feed the wolves Mike. Jamie Dimon, the chairman of the Business Roundtable, said the group of CEOs has thrown its support behind companies backing away from the practice. "When companies get where they're sort of living by so-called making the numbers, they do a lot of things that really are counter to the long-term interests of the business," Buffett said. Quarterly earnings guidance sets up executives to focus on the short-term and act in ways they might not have acted otherwise, critics of the practice say. www.cnbc.com/amp/2018/06/06/warren-buffett-and-jamie-dimon-join-forces-to-convince-ceos-to-end-quarterly-profit-forecasts.html |
|
|
|
Post by sayhey24 on Aug 4, 2022 13:57:08 GMT -5
Vanguard has over $9T assets under management and never provides guidance. Then again they are not a public company.
I would rather have Mike announce a plan for the T2 market.
|
|
|
|
Post by cretin11 on Aug 4, 2022 14:51:27 GMT -5
Vanguard has over $9T assets under management and never provides guidance. Then again they are not a public company. I would rather have Mike announce a plan for the T2 market. Correct, Vanguard is irrelevant for that reason. And yes to your T2 point. MC should be able to issue guidance and announce a plan for the T2 market. Those don't seem like unreasonable expectations. |
|
|
|
Post by lex8955 on Aug 5, 2022 4:22:11 GMT -5
Here’s some guidance from LQDA’s INSPIRE study. -- Device preference. All the Transition patients preferred or strongly preferred the YUTREPIA device when surveyed about their preferences compared to nebulized Tyvaso at Month 4. While the INSPIRE trials provide approximately one year's safety data, data from an ongoing open-label extension study will provide up to three years of long-term safety and clinical effectiveness information for YUTREPIA in PAH. The manuscript, entitled "INSPIRE: Safety and Tolerability of Inhaled YUTREPIA (Treprostinil) in Pulmonary Arterial Hypertension (PAH)" is available on the Pulmonary Circulation Journal website and at doi.org/10.1002/pul2.12119. In November 2021, the US Food & Drug Administration (FDA) issued tentative approval of YUTREPIA based on the primary endpoint of the INSPIRE trial and comparable bioavailability to Tyvaso in a Phase 1 study. Due to a regulatory stay pursuant to the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act), YUTREPIA cannot yet be marketed in the United States until the expiration of the regulatory stay or resolution of the lawsuit filed by United Therapeutics against Liquidia in June 2020 for alleged infringement of three patents related to Tyvaso. A decision from the District Court is expected before the expiration of the regulatory stay on October 27, 2022. Tyvaso is a registered trademark of United Therapeutics Corporation. From all that I read the conversion rate will be closer to 90% giving MNKD a huge chunk of change. |
|
|
|
Post by prcgorman2 on Aug 5, 2022 6:52:45 GMT -5
What else are they going to say?
“We’re tied up in court while UTHR is reporting revenue on Tyvaso which includes revenue from their recently FDA-approved Tyvaso DPI product which was approved despite a slimy Citizen’s Petition that we paid for.”?
Thanks for the FUD Elmer.
And thank you to Mango and others for finding the quotes on reasons why offering guidance is not in the best interest of a companies long-term prospects. Here’s one of the reasons why this thirst for guidance for Mannkind in particular bothers me. What the Hell can they provide guidance on? V-Go? Afrezza’s tepid growth? UTHR’s prospects for sales of Tyvaso DPI? When has anyone ever seen any CEO say, “Here’s the guidance I will give on some other companies prospects which in turn mean money for us.”?
Lastly, I’m not against guidance entirely, and did like the comment in the post from Mango (I think) that talked about a “the year ahead” kind of guidance. That would be OK, and I don’t see an issue with judging a company’s performance based on something like that, and the appropriate time to do that would be at the end of the fiscal year. It’s obviously going to be very forward-looking so caveat emptor, but puts focus where it should be, company performance, not quarterly performance.
|
|
|
|
Post by phdedieu12 on Aug 5, 2022 8:16:13 GMT -5
What else are they going to say? “We’re tied up in court while UTHR is reporting revenue on Tyvaso which includes revenue from their recently FDA-approved Tyvaso DPI product which was approved despite a slimy Citizen’s Petition that we paid for.”? Thanks for the FUD Elmer. And thank you to Mango and others for finding the quotes on reasons why offering guidance is not in the best interest of a companies long-term prospects. Here’s one of the reasons why this thirst for guidance for Mannkind in particular bothers me. What the Hell can they provide guidance on? V-Go? Afrezza’s tepid growth? UTHR’s prospects for sales of Tyvaso DPI? When has anyone ever seen any CEO say, “Here’s the guidance I will give on some other companies prospects which in turn mean money for us.”? Lastly, I’m not against guidance entirely, and did like the comment in the post from Mango (I think) that talked about a “the year ahead” kind of guidance. That would be OK, and I don’t see an issue with judging a company’s performance based on something like that, and the appropriate time to do that would be at the end of the fiscal year. It’s obviously going to be very forward-looking so caveat emptor, but puts focus where it should be, company performance, not quarterly performance. Well said! I'd also add that for a company that is now positioning itself as a technology company (or delivery device company if you will), the pipeline for new assets has become a big part of that "guidance". Of course it'd be nice that Afrezza be the blockbuster billion dollar drug that we all know it should be and would make us long very happy, but until it is, I for one will be very happy with good progress on pipeline assets. |
|
|
|
Post by agedhippie on Aug 5, 2022 16:44:34 GMT -5
... Lastly, I’m not against guidance entirely, and did like the comment in the post from Mango (I think) that talked about a “the year ahead” kind of guidance. That would be OK, and I don’t see an issue with judging a company’s performance based on something like that, and the appropriate time to do that would be at the end of the fiscal year. It’s obviously going to be very forward-looking so caveat emptor, but puts focus where it should be, company performance, not quarterly performance. I think year ahead guidance is just fine. Mike should be able to take a swing at that based on Afrezza script growth numbers and V-Go which look pretty well established, and TreT trending to 50% of UTHR nebulized sales based on the last UTHR earnings call (" ...long term, you're going to see about a 50-50 mix between the nebulized and DPI form of Tyvaso") Take those as the base and let any other revenue serve to exceed the guidance for extra points. |
|
|
|
Post by prcgorman2 on Aug 6, 2022 7:53:44 GMT -5
... Lastly, I’m not against guidance entirely, and did like the comment in the post from Mango (I think) that talked about a “the year ahead” kind of guidance. That would be OK, and I don’t see an issue with judging a company’s performance based on something like that, and the appropriate time to do that would be at the end of the fiscal year. It’s obviously going to be very forward-looking so caveat emptor, but puts focus where it should be, company performance, not quarterly performance. I think year ahead guidance is just fine. Mike should be able to take a swing at that based on Afrezza script growth numbers and V-Go which look pretty well established, and TreT trending to 50% of UTHR nebulized sales based on the last UTHR earnings call (" ...long term, you're going to see about a 50-50 mix between the nebulized and DPI form of Tyvaso") Take those as the base and let any other revenue serve to exceed the guidance for extra points. I agree, and it’s a pretty safe bet as long as they plan to keep V-Go in the mix for another year, but because it is safe, and known, is that really the “guidance” cretin and others want to see? |
|
|
|
Post by cretin11 on Aug 6, 2022 13:49:08 GMT -5
... Lastly, I’m not against guidance entirely, and did like the comment in the post from Mango (I think) that talked about a “the year ahead” kind of guidance. That would be OK, and I don’t see an issue with judging a company’s performance based on something like that, and the appropriate time to do that would be at the end of the fiscal year. It’s obviously going to be very forward-looking so caveat emptor, but puts focus where it should be, company performance, not quarterly performance. I think year ahead guidance is just fine. Mike should be able to take a swing at that based on Afrezza script growth numbers and V-Go which look pretty well established, and TreT trending to 50% of UTHR nebulized sales based on the last UTHR earnings call (" ...long term, you're going to see about a 50-50 mix between the nebulized and DPI form of Tyvaso") Take those as the base and let any other revenue serve to exceed the guidance for extra points. Baby steps might be the way to go, would be better than nothing. But after all these years would be good to see the training wheels discarded. Fingers crossed. |
|
